General discussion, page-4767

Hi Mr F , I would have to disagree somewhat with the sentiment of your post .

Each of us is entitled to their own view I agree and we can all be somewhat entrenched in our views ,however , where I disagree is that one needs to be aware of the stage at which this gem is at . It has had successful results in 675 trials and has been building .

The company obviously has to progress it’s trials 675 and others , FDA is in pipeline and there is a listing in wings in the US - the Boards strategy is sound and they are taking all the rights steps engaging all the qualified experts that is all we can ask of them.

Processing medical IP is complex and takes time and patience and the progression of the IP to FDA is in the hands of third parties . All indicators are positive and when they get it right and I suspect they will given the talent and expertise they have on board it will be potentially massive imo . So in my view I do not think we as investors have cause to criticise . They are on track and clearly the proof will be in the results but to suggest given what the company has done to date and how advanced they are in this very technical space that the criteria is not selling anything or maybes is respectfully off the mark . The measure of success will be the trials and FDA on 675 or other trials which are game changers . Look at GW Pharma and other IP plays as an example . Given what is in the pipeline imo it is undervalued here that is my unbiased opinion based on fundamentals and pier comparison sales is not the criteria anyone can sell oils this is a bigger play . That is my view